Trade Unlisted is not regulated by the Securities and Exchange Board of India (SEBI). Investments in unlisted securities involve significant risk, including the risk of complete loss of capital. The filing of a Draft Red Herring Prospectus (DRHP) does not guarantee that an Initial Public Offering (IPO) will occur. Unlisted securities are inherently illiquid, price discovery may be limited, and exit opportunities may not materialize.
Trade Unlisted provides news, insights, and general market information for informational and educational purposes only. The content should not be construed as financial, investment, legal, or tax advice. Trade Unlisted does not act as a broker, investment advisor, fiduciary, or intermediary, and does not endorse, recommend, solicit, or validate any investment opportunity. Users are solely responsible for conducting their own independent due diligence before making any financial or investment decisions.
All information is derived from publicly available sources and market observations. While reasonable care is taken in preparing content, Trade Unlisted makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of the information provided. Users should independently verify all information prior to relying on it.
From “Burn” to “Earn”: PharmEasy Eyes Profitability by FY27
- When API Holdings (parent of PharmEasy) appointed Rahul Guha as MD & CEO in August, the company shifted from aggressive growth to a lean, profit-first approach. The focus is now on cutting costs, optimising capital, and pushing high-margin products and services.
- By the first half of FY26, the group reportedly turned EBITDA-positive (excluding ESOP costs). The goal: full-year EBITDA profitability and PAT (excluding its diagnostics arm) by March 2027.
What Changed
- The group refinanced high-cost borrowings, swapping out older expensive debt with about ₹1,700 crore of lower-cost NCDs, and sold a ~10% stake in its diagnostics arm Thyrocare Technologies Ltd. for ₹668 crore. This has reduced interest burden and improved the balance sheet.
- Supply-chain dynamics improved: medicine procurement that was earlier only ~40% internal is now around 85% internal, lifting gross margins.
- PharmEasy is increasingly focusing on recurring, high-margin segments: chronic disease medicines, diagnostics, subscriptions, private-label products, and allied health services — moving away from low-margin, discount-heavy models.
Financial Context
- API Holdings posted revenue of ₹5,872.2 crore in FY25; its EBITDA loss narrowed, and net loss shrank significantly compared to prior years.
- Its diagnostics arm, Thyrocare, continues to deliver profit, supporting the group’s turnaround strategy.
What It Means for Investors
- The strategic overhaul appears to be showing early results — cash burn is down, margins improving, and profitability goals are clearly defined.
- Reduction in debt burden and stronger cash-flow management could set up the company for a better valuation, potential IPO, or value-unlocking event once profitability stabilises.
- Diversified revenue streams (medicines, diagnostics, services, private label) reduce dependency on discounts and may offer more stable long-term growth.
Comments